Details for Patent: 9,283,216
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 9,283,216 protect, and when does it expire?
Patent 9,283,216 protects TARGINIQ and is included in one NDA.
This patent has twenty patent family members in nine countries.
Summary for Patent: 9,283,216
Title: | Abuse-resistant controlled-release opioid dosage form |
Abstract: | Abuse-resistant, controlled release opioid tablets are a combination containing an opioid antagonist such as naloxone at a level above that needed to suppress the euphoric effect of the opioid, if the combination were crushed to break the controlled release properties causing the opioid and opioid antagonist to be released as a immediate release product as a single dose. The controlled release nature of the table prevents the accumulation of orally effective amounts of opioid antagonist when taken normally. The opioid antagonist is contained in a controlled-release matrix and released, over time, with the opioid. |
Inventor(s): | Caruso; Frank S. (Colts Neck, NJ), Kao; Huai-Hung (Syosset, NY) |
Assignee: | Purdue Pharma L.P. (Stamford, CT) |
Application Number: | 14/859,195 |
Patent Claim Types: see list of patent claims | Composition; Dosage form; Use; |
Drugs Protected by US Patent 9,283,216
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Purdue Pharma Lp | TARGINIQ | naloxone hydrochloride; oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205777-001 | Jul 23, 2014 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE | See Plans and Pricing | |||
Purdue Pharma Lp | TARGINIQ | naloxone hydrochloride; oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205777-002 | Jul 23, 2014 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE | See Plans and Pricing | |||
Purdue Pharma Lp | TARGINIQ | naloxone hydrochloride; oxycodone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 205777-003 | Jul 23, 2014 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | MANAGEMENT OF PAIN SEVERE ENOUGH TO REQUIRE DAILY, AROUND-THE-CLOCK, LONG TERM OPIOID TREATMENT AND FOR WHICH ALTERNATIVE TREATMENT OPTIONS ARE INADEQUATE | See Plans and Pricing | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,283,216
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | 493130 | See Plans and Pricing | |||
Australia | 2002305559 | See Plans and Pricing | |||
Australia | 2008202967 | See Plans and Pricing | |||
Canada | 2446550 | See Plans and Pricing | |||
China | 1525851 | See Plans and Pricing | |||
Germany | 60238756 | See Plans and Pricing | |||
European Patent Office | 1387673 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |